Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Ann Pharmacother ; 51(2): 101-110, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27733668

RESUMO

BACKGROUND: There are limited data on the efficacy of symptom-triggered therapy for alcohol withdrawal syndrome (AWS) in the intensive care unit (ICU). OBJECTIVE: To evaluate the safety and efficacy of a symptom-triggered benzodiazepine protocol utilizing Riker Sedation Agitation Scale (SAS) scoring for the treatment of AWS in the ICU. METHODS: We performed a before-and-after study in a medical ICU. A protocol incorporating SAS scoring and symptom-triggered benzodiazepine dosing was implemented in place of a protocol that utilized the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale and fixed benzodiazepine dosing. RESULTS: We enrolled 167 patients (135 in the preintervention and 32 in the postintervention group). The median duration of AWS was shorter in the postintervention (5, interquartile range [IQR] = 4-8 days) than in the preintervention group (8, IQR = 5-12 days; P < 0.01). Need for mechanical ventilation (31% vs 57%, P = 0.01), median ICU length of stay (LOS; 4, IQR = 2-7, vs 7, IQR = 4-11 days, P = 0.02), and hospital LOS (9, IQR = 6-13, vs 13, IQR = 9-18 days; P = 0.01) were less in the postintervention group. There was a reduction in mean total benzodiazepine exposure (74 ± 159 vs 450 ± 701 mg lorazepam; P < 0.01) in the postintervention group. CONCLUSION: A symptom-triggered benzodiazepine protocol utilizing SAS in critically ill patients is associated with a reduction in the duration of AWS treatment, benzodiazepine exposure, need for mechanical ventilation, and ICU and hospital LOS compared with a CIWA-Ar-based protocol using fixed benzodiazepine dosing.


Assuntos
Benzodiazepinas/uso terapêutico , Hipnóticos e Sedativos/uso terapêutico , Síndrome de Abstinência a Substâncias/diagnóstico , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Adulto , Benzodiazepinas/administração & dosagem , Protocolos Clínicos , Estado Terminal , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Humanos , Hipnóticos e Sedativos/administração & dosagem , Unidades de Terapia Intensiva , Tempo de Internação , Lorazepam/administração & dosagem , Lorazepam/uso terapêutico , Masculino , Pessoa de Meia-Idade , Respiração Artificial , Índice de Gravidade de Doença , Síndrome de Abstinência a Substâncias/terapia
2.
J Health Care Poor Underserved ; 24(3): 1353-63, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23974404

RESUMO

Significant race-related disparities persist in the U.S. regarding access to health services. Initiatives to reduce such disparities have often focused on expanding health insurance coverage for vulnerable populations. Based on our analysis of 2010 data from the National Health Interview Survey, we found that race is a much greater factor than insurance status in accounting for disparities in access to health services. Expanding health insurance through reform initiatives such as the Patient Protection and Affordable Care Act may have relatively little impact on reducing racial and ethnic disparities in the US.


Assuntos
Disparidades nos Níveis de Saúde , Pessoas sem Cobertura de Seguro de Saúde/etnologia , Grupos Raciais , Adolescente , Adulto , Intervalos de Confiança , Acessibilidade aos Serviços de Saúde , Inquéritos Epidemiológicos , Humanos , Pessoa de Meia-Idade , Razão de Chances , Patient Protection and Affordable Care Act , Análise de Regressão , Estados Unidos , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA